Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03466203 | Safety Study of LLF580 in Obese Volunteers | PHASE1 | COMPLETED | 61 | — | — | Feb 26, 2018 | Nov 13, 2019 | Oct 12, 2021 | 7 | United States |
To assess the safety and tolerability in obese subjects following repeated dosing of LLF580 by subcutaneous (SC) injection over 12 weeks.
| Arm | Type | Description |
|---|---|---|
| LLF580 | EXPERIMENTAL | LLF580 every 28 days \* 3 |
| Placebo | PLACEBO_COMPARATOR | Placebo to LLF580 every 28 days \* 3 |
| Name | Type | Description |
|---|---|---|
| LLF580 | BIOLOGICAL | LLF580 300mg |
| Placebo | DRUG | Placebo to LLF580 |
Inclusion Criteria: * Body mass index (BMI) within the range of 30 to 45 kg/m2, inclusive, with ethnic adjustment (≥27.5 kg/m2 for Asian individuals). * Fasting triglyceride 150 - 500 mg/dL (1.69 - 5.65 mmol/L), inclusive, at screening. * Able to communicate well with the investigator, to understan...